NCT05547464 - Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers | Biotech Hunter

Enrollment

497

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions

Tuberculosis

Interventions

BIOLOGICAL

BNT164a1

Multi-antigen ribonucleic acid (RNA) vaccine for active immunization against tuberculosis administered as intramuscular injection

BIOLOGICAL

BNT164b1

Multi-antigen RNA vaccine for active immunization against tuberculosis administered as intramuscular injection

OTHER

Placebo

Trial Locations (8)

Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC), Maputo

The Aurum Institute Tembisa CRC Clinic 4, Tembisa

Centro de Investigação em Saúde de Manhiça (CISM), Manhiça

Africa Health Research Institute (AHRI), Mtubatuba

CAPRISA eThekweni Clinical Research Site, Berea

South African Tuberculosis Vaccine Initiative SATVI, Cape Town

Centre for Lung Infection and Immunity UCT Lung Institute, Cape Town

Desmond Tutu Health Foundation - Masiphumele Research Office, Cape Town